论文部分内容阅读
目的探讨曲美他嗪治疗冠心病并左心功能不全的临床疗效,并分析其药理机制。方法 80例冠心病并左心功能不全患者,随机分为对照组和观察组,各40例。对照组采用常规疗法,观察组在对照组基础上加用曲美他嗪治疗,比较两组临床疗效。结果对照组再住院率为22.5%,死亡率为15.0%,高于观察组的5.0%、2.5%,差异有统计学意义(P<0.05)。观察组心功能Ⅱ级占72.5%,高于对照组32.5%,差异有统计学意义(P<0.05)。两组治疗前左室舒张末内径(LVEDD)、左室射血分数(LVEF)、超敏C反应蛋白(hs-CRP)及血清脑钠肽(BNP)比较差异无统计学意义(P>0.05);治疗后两组上述指标均明显优于本组治疗前,且观察组均明显优于对照组,差异有统计学意义(P<0.05)。结论曲美他嗪治疗冠心病并左心功能不全患者效果优良,可明显改善患者心功能,降低再住院率与死亡率,改善预后,进而改善患者生存质量,值得推广。
Objective To investigate the clinical efficacy of trimetazidine in the treatment of coronary heart disease and left ventricular dysfunction, and to analyze its pharmacological mechanism. Methods Eighty patients with coronary heart disease and left ventricular dysfunction were randomly divided into control group and observation group, 40 cases each. The control group received conventional therapy. The observation group was treated with trimetazidine on the basis of the control group, and the clinical efficacy was compared between the two groups. Results In the control group, the rate of rehospitalization was 22.5% and the mortality rate was 15.0%, which was higher than that of the observation group (5.0% and 2.5%, respectively) (P <0.05). The observation group had 72.5% of grade Ⅱ cardiac function, which was higher than that of the control group (32.5%), the difference was statistically significant (P <0.05). There was no significant difference in LVEDD, LVEF, hs-CRP and BNP between the two groups before treatment (P> 0.05 ). After treatment, the above indexes in both groups were significantly better than those before treatment, and the observation group were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion Trimetazidine treatment of coronary heart disease and left ventricular dysfunction in patients with excellent results, can significantly improve the patient’s cardiac function, reduce rehospitalization and mortality, improve prognosis, thereby improving the quality of life of patients, it is worth promoting.